Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Euronext Paris  >  Stentys    STNT   FR0010949404

STENTYS (STNT)
Mes dernières consult.
Most popular
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

STENTYS : 16 May 2012: Apposition III Results

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/16/2012 | 07:33pm CEST
FOR IMMEDIATE RELEASE NEWS RELEASE

Contact: Ronald Trahan, APR, President, Ronald Trahan Associates Inc., +1-508-359-4005,x108

STENTYS Self-Apposing® Stent shows very low mortality at one month in 1,000 high risk heart attack patients APPOSITION III study results reveal mortality at 1.2% compared to 3.5% in pooled analysis of conventional stents

PRINCETON, N.J., and PARIS, May 16, 2012 - STENTYS S.A. (STNT.PA), a medical technology company commercializing the world's first and only Self-Apposing® Stent to treat Acute Myocardial Infarction (AMI), announced today the definite results on the 1,000 patient APPOSITION III clinical study at one month after treatment of a severe heart attack.

The 30-day rate of MACE (Major Adverse Cardiac Events) and death were compared to a pooled analysis conducted by the ACTION Study Group (Pitié-Salpêtrière Hospital, Prof. G. Montalescot) of all prior recent trials with conventional stents in heart attack patients.

APPOSITION III results showed a MACE rate of 3.5% when conventional stents are at an average of 6%;

the death rate was 1.2% with STENTYS when compared to 3.5% with conventional stents.

"When the current guideline on balloon post-dilation was applied, the MACE rate was even lower at 2.5%, which is a drastic improvement for our patients", commented Dr Giovanni Amoroso, OLVG Hospital, Amsterdam, The Netherlands and principal investigator of the study.

"These impressive clinical results validate our Self-Apposing® Stent as the best solution for treating heart attack patients in routine practice," said Gonzague Issenmann, CEO and co-founder of STENTYS.

The STENTYS Self-Apposing® Stent solves the stent-sizing dilemma that cardiologists are confronted with when treating heart attack patients with conventional stents. It "fits snugly" into the contour of a blood vessel, and its shape and diameter adapt as the vessel dilates and the initial clot dissolves during the post- AMI phase, eliminating malapposition and its major complications seen with all other conventional stents.

About the APPOSITION III Study

APPOSITION III is a prospective, single arm, multi-center (50 hospitals across Europe) post-market trial to assess the long term performance of STENTYS Self-Apposing stent in routine clinical practice in 1,000 patients suffering from ST-Elevation Myocardial infarction ("STEMI"). The trial's primary endpoint is Major Adverse Cardiac Events ("MACE") at 12 months. MACE is defined at as cardiac death, target vessel re-MI, emergent CABG, or clinically- driven TVR by percutaneous or surgical methods at 12 months. The trial's secondary endpoints are MACE at 30 days and 24 months post-procedure. The study completed enrolment in January 2012. After a preliminary analysis of the first
350 patients, the guideline on balloon post-dilation was modified from a limitation (only when residual stenosis above
30%, cohort A) to a general recommendation (cohort B).
MACE rate at 30 days was 3.5% for the whole study, and 2.5% when post-dilation was applied. Mortality represented
1.2% on the whole study.
1
STENTYS expects to release the primary endpoint interim results of the APPOSITION III study in 600 patients during
Q4 2012 and the full results on 1,000 patients in H1 2013.

About STENTYS

Based in Princeton, N.J., and Paris, STENTYS has developed a new generation of stents to treat acute myocardial infarction (AMI). Founded by Jacques Séguin, M.D., Ph.D., (also founder of CoreValve, which was acquired by Medtronic) and Gonzague Issenmann, STENTYS received CE-marking for its flagship products in 2010. Its Self- Apposing® stent adapts to the anatomic changes of arteries in the post-infarction phase and thus prevents the malapposition problem associated with conventional stents. STENTYS has commenced marketing activities in several European countries.

This announcement is not an offer for sale of securities in the United States. The securities referred to herein have not been offered or sold in the United States and may not be offered or sold in the United States of America, except pursuant to a registration statement under the U.S. Securities Act of 1933, as amended (the "Securities Act"), or pursuant to an exemption from registrations thereunder. This press release is being issued pursuant to and in accordance with Rule 135c under the Securities Act.

# # # # #

2

distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on STENTYS
08/17 STENTYS : Researchers from University of Amsterdam Report Findings in Heart Atta..
07/28 27 JULY 2017 : STENTYS Completes Enrollment of the TRUNC Study
07/12 12 JULY 2017 : Revenues of €1.7 million in the second quarter of 2017
07/07STENTYS SAS : half-yearly sales release
06/22 22 JUNE 2017 : Report on the Combined Shareholders' Meeting of June 22, 2017
05/24 24 MAY 2017 : Follow-Up of the APPOSITION IV and OPEN II Clinical Trials at Resp..
04/03 03 APRIL 2017 : STENTYS is strengthening its Board by co-opting two new independ..
03/17STENTYS SAS : annual earnings release
03/09 STENTYS : Studies from University of Amsterdam Yield New Information about Stent..
01/12 12 JANUARY 2017 : 2016 Annual Revenues up 20% at €7.3 Million
More news
News from SeekingAlpha
04/24 Stentys reports Q1 results
01/12 Stentys reports Q4 results
2016 Stentys reports Q3 results
2016 Stentys reports 1H results
2016 Stentys reports Q2 results
Financials (€)
Sales 2017 8,90 M
EBIT 2017 -7,00 M
Net income 2017 -7,00 M
Finance 2017 0,35 M
Yield 2017 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales 2017 3,35x
EV / Sales 2018 2,59x
Capitalization 30,2 M
Chart STENTYS
Duration : Period :
Stentys Technical Analysis Chart | STNT | FR0010949404 | 4-Traders
Technical analysis trends STENTYS
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 2
Average target price 2,50 €
Spread / Average Target 48%
EPS Revisions
Managers
NameTitle
Christophe Lottin Chief Executive Officer & Director
Michel Darnaud Chairman
André Lerebours Chief Financial Officer
Hikmat Hojeibane Chief Technology Officer
David Bouchez Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
STENTYS-33.46%36
MEDTRONIC PLC17.10%113 356
BAXTER INTERNATIONAL37.28%33 166
C R BARD INC41.64%23 124
ZIMMER BIOMET HOLDINGS INC7.93%22 521
HOYA CORPORATION27.92%22 463